Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial

Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was significantly superior to tamoxifen in terms of efficacy and safety in the adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansel, R, Locker, G, Fallowfield, L, Benedict, Á, Jones, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360294/
https://www.ncbi.nlm.nih.gov/pubmed/17622238
http://dx.doi.org/10.1038/sj.bjc.6603804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360294/
https://www.ncbi.nlm.nih.gov/pubmed/17622238
http://dx.doi.org/10.1038/sj.bjc.6603804

Ejemplares similares